Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function

Summary

Platelet and monocyte activation may contribute to hemolytic anemia, thrombocytopenia and renal failure associated with the hemolytic uremic syndrome (HUS) caused by Escherichia coli O157:H7. Since Shiga toxins (Stxs) and lipopolysaccharide (LPS) from this bacterium are implicated in the pathogenesis of HUS, we examined whether stimulation of THP-1 human monocytic cells by Shiga toxin 2 (Stx2) and LPS can lead to the activation of platelet function. We now show that Stx2 caused THP-1 cells to release the chemokines IL-8, MDC, and RANTES and that the presence of LPS further stimulated this release. IL-8 was produced in greatest amount and was an effective co-agonist for inducing platelet aggregation. Primary human monocytes also released large amounts of IL-8 in response to LPS and Stx2. Factors released by THP-1 cells exposed to Stx2 and LPS activated platelet function as evidenced by increased aggregation, serotonin secretion, P-selectin exposure and by the formation of stable platelet-monocyte aggregates. Our data therefore show that monocytes exposed to E. coli-derived Stx2 and LPS release factors which activate platelet function.

Keywords

Shiga toxin - lipopolysaccharide (LPS) - platelets - aggregation - chemokines - monocytes (THP-1) - secretion - hemolytic uremic syndrome (HUS) - IL-8 - RANTES

• References

• 1 Gasser C, Gautieer E, Steck A. et al. Hämolytischuramische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytishen Anämien. Schweiz Med Wochenschr 1955; 85: 905-909.
• 2 Huppertz H, Busch D, Schmidt H. et al. Diarrhea in young children associated with Escherichia coli non-O157 organisms that produce Shiga-like toxin. J Pediatr 1996; 128: 341-6.
• 3 Ludwig K, Sarkim V, Bitzan M. et al. Shiga toxinproducing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2002; 40: 1773-82.
• 4 Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol. 2004 121 Suppl S81-88.
• 5 Appiani AC, Edefonti A, Bettinelli A. The relationship between plasma levels of the factor VIII complex and platelet release products β-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome. Clin Nephrol 1982; 17: 195-9.
• 6 Walters MD, Levin M, Smith C. et al. Intravascular platelet activation in the hemolytic uremic syndrome. Kidney Int 1988; 33: 107-15.
• 7 Yoshimura K, Fujii J, Yutsudo T. et al. No direct effects of Shiga toxin 1 and 2 on the aggregation of human platelets in vitro. Thromb Haemost 1998; 80: 529-30.
• 8 Thorpe CM, Flaumenhaft R, Hurley B. et al. Shiga toxins do not directly stimulate alpha-granule secretion or enhance aggregation of human platelets. Acta Haematol 1999; 102: 51-5.
• 9 Viisoreanu D, Polanowska-Grabowska R, Suttitanamongkol S. et al Human platelet aggregation is not altered by Shiga toxins 1 or 2. Thromb Res 2000; 98: 403-10.
• 10 Koster F, Levin J, Walker L. et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med 1978; 298: 927-33.
• 11 Bitzan M, Moebius E, Ludwig K. et al. High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic uremic syndrome. J Pediatr 1991; 119: 380-5.
• 12 Karpman D, Connell H, Svensson M. et al. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997; 175: 611-20.
• 13 van Setten PA, Monnens LA, Verstraten RG. et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996; 88: 174-83.
• 14 Harrison LM, van Haaften WCE, Tesh VL. Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect Immun 2004; 72: 2618-27.
• 15 Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-50.
• 16 Shenkman B, Brill A, Brill G. et al. Differential response of platelets to chemokines: RANTES non-competitively inhibits stimulatory effect of SDF-1alpha. J Thromb Haemost 2004; 2: 154-60.
• 17 Suttitanamongkol S, Gear AR. ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC. FEBS Lett 2001; 490: 84-7.
• 18 Gear AR. Rapid reactions of platelets studied by a quenched-flow approach: aggregation kinetics. J Lab Clin Med 1982; 100: 866-86.
• 19 Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-Report–Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis Thromb Haemost 1986; 55: 415-35.
• 20 Jones GD, Carty DJ, Freas DL. et al. Effects of separate proteolytic and high-affinity binding activities of human thrombin on rapid platelet activation. A quenched-flow study. Biochem J 1989; 262: 611-6.
• 21 Karmali MA, Petric M, Lim C. et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli . J Infect Dis 1985; 151: 775-82.
• 22 Taylor FB, Tesh VL, DeBault L. et al. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154: 1285-99.
• 23 Ghosh SA, Polanowska-Grabowska R, Fujii J. et al. Shiga toxin binds to activated platelets. J Thromb Haemost 2004; 2: 499-506.
• 24 Brueckmann M, Hoffmann U, DeRossi L. et al. Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine 2004; 26: 106-13.
• 25 Sakamoto H, Aikawa M, Hill CC. et al. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. Circulation 2001; 104: 109-14.
• 26 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86: 214-21.
• 27 Karpman D, Papadopoulou D, Nilsson K. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-8.
• 28 Baltus T, von Hundelshausen P, Mause SF. et al. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78: 435-41.
• 29 Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol 2004; 15: 553-8.
• 30 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 31 Leytin V, Shakoor S, Mody M. Sepsis- and endotoxemia- generated cytokines do not trigger activation of human platelets. Crit Care Med 2002; 30: 27713.
• 32 Gear AR, Suttitanamongkol S. Viisoreanu et al. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97: 937-45.
• 33 Marcus AJ, Broekman MJ, Drosopoulos JH. et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351-60.
• 34 Robson SC, Kaczmarek E, Siegel JB. et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-63.
• 35 Steen VM, Holmsen H, Aarbakke G. The plateletstimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70: 506-13.
• 36 Clemetson KJ, Clemetson JM, Proudfoot AE. et al. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-54.
• 37 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.
• 38 Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105: 2130-2.
• 39 Gawaz M, Dickfeld T, Bogner C. et al. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997; 23: 379-85.
• 40 Nieuwland R, Berckmans RJ, McGregor S. et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
• 41 Ogura H, Kawasaki T, Tanaka H. et al. Activated platelets enhance microparticle formation and plateletleukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-9.
• 42 Brass L, Molino M. Protease-activated G proteincoupled receptors on human platelets and endothelial cells. Thromb Haemost 1997; 78: 234-41.
• 43 Schmid DI, Kohan DE. Effect of shigatoxin-1 on arachidonic acid release by human glomerular epithelial cells. Kidney Int 2001; 60: 1026-36.
• 44 Tonshoff B, Momper R, Kuhl PG. et al. Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. Kidney Int 1990; 37: 1134-41.
• 45 Noris M, Benigni A, Siegler R. et al. Renal prostacyclin biosynthesis is reduced in children with hemolytic- uremic syndrome in the context of systemic platelet activation. Am J Kidney Dis 1992; 20: 144-9.
• 46 Harrison LM, van den Hoogen C, van Haaften WC. et al. Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides. Infect Immun 2005; 73: 403-12.
• 47 Montrucchio G, Bosco O, Del Sorbo L. et al. Mechanisms of the priming effect of low doses of lipopolysaccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost 2003; 90: 872-81.